Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report.
Although the glycoprotein IIb/IIIa receptor inhibitors have improved outcomes of patients with acute coronary syndrome (ACS), therapy with these agents may cause thrombocytopenia with bleeding complications. This adverse effect is seemed to be rare with tirofiban. In this report, we describe a case of acute profound thrombocytopenia within two hours of tirofiban administration and review the differential diagnosis and the management of thrombocytopenia.
Demirkan
Burcu
B
Yüksek Ihtisas Hospital, Cardiology Clinic, Ankara, Turkey. burcume@yahoo.com
Guray
Yesim
Y
Guray
Umit
U
Korkmaz
Sule
S
D000208:Acute Disease; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban